Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma, Phase III

SWOG S9005: double blind phase III randomized trial of the anti-progestin agent mifepristone in the treatment of unresectable meningioma

Y Ji;C Rankin;S Grunberg;J Ahmadi;J Townsend;L Feun;R Fredericks;CA Russell;F Kabbinavar;KJ Stelzer;A Schott;C Verschraegen Journal of Clinical Oncology Dec 1;33(34):4093-4098

PMid: PMID26527781 | PMC number: PMC4669593

SWOG S9005: double blind phase III randomized trial of the anti-progestin agent mifepristone in the treatment of unresectable meningioma

H Ji;C Rankin;S Grungerg;J Ahmadi;L Feun;R Fredericks;C Russell;F Kabbinavar;K Stelzer;A Schott;C Verschraegen Journal of Clinical Oncology 33:5s (suppl; abstr e17084); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), publication only;

Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma.

SM Grunberg;C Rankin;J Townsend;J Ahmadi;L Feun;R Fredericks;C Russell;F Kabbinavar;GR Barger;KJ Stelzer Proc of the American Society of Clinical Oncology 20:56a(#222)

Alterations in thyroid function, gonadotropins and sex steroids consequent to long-term mifepristone administration

O Heikinheimo;S Ranta;S Grunberg;IM Spitz Satellite Symp of the 6th Inter Congress on Hormones and Cancer :61

Alterations in the pituitary-thyroid and pituitary-adrenal axes-consequences of long-term mifepristone treatment.

O Heikinheimo;S Ranta;S Grunberg;P Lahteenmaki;IM Spitz Metabolism 46(3):292-296

Suppression of gonadotropin secretion in post-menopausal women during long-term mifepristone administration.

O Heikinhemio;S Rantal;S Grunberg;IM Spitz Proc of the 79th Annual Meeting of the Endocrine Society (#P2-367):376